Selected research
Industry Research
Inhalation CDMO Industry Research Report 2026
Market perspective
The global Inhalation CDMO market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Inhalation CDMO market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Inhalation CDMO market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Inhalation CDMO market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Inhalation CDMO include Aptar Pharma, Bend Bioscience, Bespak, Catalent, CritiTech, Enteris Biopharma, Experic, HCmed and Hovione, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Inhalation CDMO market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Inhalation CDMO.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Inhalation CDMO Market by Company
Aptar Pharma
Bend Bioscience
Bespak
Catalent
CritiTech
Enteris Biopharma
Experic
HCmed
Hovione
Iconovo
Kindeva
Lonza
Particle Sciences
Proveris
Recipharm
Renejix
Ritedose
Vectura
Sanner
Inhalation CDMO Segment by Type
Soft Mist Inhalers (SMIs)
Dry Powder Inhalers (DPIs)
Metered Dose Inhalers (MDIs)
Others
Inhalation CDMO Segment by Application
Commercial
Academic Research
Others
Inhalation CDMO Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Inhalation CDMO market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Inhalation CDMO and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Inhalation CDMO.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Inhalation CDMO companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Soft Mist Inhalers (SMIs)
- Dry Powder Inhalers (DPIs)
- Metered Dose Inhalers (MDIs)
- Others
Applications
- Commercial
- Academic Research
- Others
Companies covered
- Aptar Pharma
- Bend Bioscience
- Bespak
- Catalent
- CritiTech
- Enteris Biopharma
- Experic
- HCmed
- Hovione
- Iconovo
- Kindeva
- Lonza
- Particle Sciences
- Proveris
- Recipharm
- Renejix
- Ritedose
- Vectura
- Sanner
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Inhalation CDMO by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Soft Mist Inhalers (SMIs)
- 2.2.3 Dry Powder Inhalers (DPIs)
- 2.2.4 Metered Dose Inhalers (MDIs)
- 2.2.5 Others
- 2.3 Inhalation CDMO by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Commercial
- 2.3.3 Academic Research
- 2.3.4 Others
- 2.4 Assumptions and Limitations
3 Inhalation CDMO Breakdown Data by Type
- 3.1 Global Inhalation CDMO Historic Market Size by Type (2021-2026)
- 3.2 Global Inhalation CDMO Forecasted Market Size by Type (2027-2032)
4 Inhalation CDMO Breakdown Data by Application
- 4.1 Global Inhalation CDMO Historic Market Size by Application (2021-2026)
- 4.2 Global Inhalation CDMO Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Inhalation CDMO Market Perspective (2021-2032)
- 5.2 Global Inhalation CDMO Growth Trends by Region
- 5.2.1 Global Inhalation CDMO Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Inhalation CDMO Historic Market Size by Region (2021-2026)
- 5.2.3 Inhalation CDMO Forecasted Market Size by Region (2027-2032)
- 5.3 Inhalation CDMO Market Dynamics
- 5.3.1 Inhalation CDMO Industry Trends
- 5.3.2 Inhalation CDMO Market Drivers
- 5.3.3 Inhalation CDMO Market Challenges
- 5.3.4 Inhalation CDMO Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Inhalation CDMO Players by Revenue
- 6.1.1 Global Top Inhalation CDMO Players by Revenue (2021-2026)
- 6.1.2 Global Inhalation CDMO Revenue Market Share by Players (2021-2026)
- 6.2 Global Inhalation CDMO Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Inhalation CDMO Head Office and Area Served
- 6.4 Global Inhalation CDMO Players, Product Type & Application
- 6.5 Global Inhalation CDMO Manufacturers Established Date
- 6.6 Global Inhalation CDMO Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Inhalation CDMO Market Size (2021-2032)
- 7.2 North America Inhalation CDMO Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Inhalation CDMO Market Size by Country (2021-2026)
- 7.4 North America Inhalation CDMO Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Inhalation CDMO Market Size (2021-2032)
- 8.2 Europe Inhalation CDMO Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Inhalation CDMO Market Size by Country (2021-2026)
- 8.4 Europe Inhalation CDMO Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Inhalation CDMO Market Size (2021-2032)
- 9.2 Asia-Pacific Inhalation CDMO Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Inhalation CDMO Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Inhalation CDMO Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Inhalation CDMO Market Size (2021-2032)
- 10.2 South America Inhalation CDMO Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Inhalation CDMO Market Size by Country (2021-2026)
- 10.4 South America Inhalation CDMO Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Inhalation CDMO Market Size (2021-2032)
- 11.2 Middle East & Africa Inhalation CDMO Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Inhalation CDMO Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Inhalation CDMO Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Aptar Pharma
- 12.1.1 Aptar Pharma Company Information
- 12.1.2 Aptar Pharma Business Overview
- 12.1.3 Aptar Pharma Revenue in Inhalation CDMO Business (2021-2026)
- 12.1.4 Aptar Pharma Inhalation CDMO Product Portfolio
- 12.1.5 Aptar Pharma Recent Developments
- 12.2 Bend Bioscience
- 12.2.1 Bend Bioscience Company Information
- 12.2.2 Bend Bioscience Business Overview
- 12.2.3 Bend Bioscience Revenue in Inhalation CDMO Business (2021-2026)
- 12.2.4 Bend Bioscience Inhalation CDMO Product Portfolio
- 12.2.5 Bend Bioscience Recent Developments
- 12.3 Bespak
- 12.3.1 Bespak Company Information
- 12.3.2 Bespak Business Overview
- 12.3.3 Bespak Revenue in Inhalation CDMO Business (2021-2026)
- 12.3.4 Bespak Inhalation CDMO Product Portfolio
- 12.3.5 Bespak Recent Developments
- 12.4 Catalent
- 12.4.1 Catalent Company Information
- 12.4.2 Catalent Business Overview
- 12.4.3 Catalent Revenue in Inhalation CDMO Business (2021-2026)
- 12.4.4 Catalent Inhalation CDMO Product Portfolio
- 12.4.5 Catalent Recent Developments
- 12.5 CritiTech
- 12.5.1 CritiTech Company Information
- 12.5.2 CritiTech Business Overview
- 12.5.3 CritiTech Revenue in Inhalation CDMO Business (2021-2026)
- 12.5.4 CritiTech Inhalation CDMO Product Portfolio
- 12.5.5 CritiTech Recent Developments
- 12.6 Enteris Biopharma
- 12.6.1 Enteris Biopharma Company Information
- 12.6.2 Enteris Biopharma Business Overview
- 12.6.3 Enteris Biopharma Revenue in Inhalation CDMO Business (2021-2026)
- 12.6.4 Enteris Biopharma Inhalation CDMO Product Portfolio
- 12.6.5 Enteris Biopharma Recent Developments
- 12.7 Experic
- 12.7.1 Experic Company Information
- 12.7.2 Experic Business Overview
- 12.7.3 Experic Revenue in Inhalation CDMO Business (2021-2026)
- 12.7.4 Experic Inhalation CDMO Product Portfolio
- 12.7.5 Experic Recent Developments
- 12.8 HCmed
- 12.8.1 HCmed Company Information
- 12.8.2 HCmed Business Overview
- 12.8.3 HCmed Revenue in Inhalation CDMO Business (2021-2026)
- 12.8.4 HCmed Inhalation CDMO Product Portfolio
- 12.8.5 HCmed Recent Developments
- 12.9 Hovione
- 12.9.1 Hovione Company Information
- 12.9.2 Hovione Business Overview
- 12.9.3 Hovione Revenue in Inhalation CDMO Business (2021-2026)
- 12.9.4 Hovione Inhalation CDMO Product Portfolio
- 12.9.5 Hovione Recent Developments
- 12.10 Iconovo
- 12.10.1 Iconovo Company Information
- 12.10.2 Iconovo Business Overview
- 12.10.3 Iconovo Revenue in Inhalation CDMO Business (2021-2026)
- 12.10.4 Iconovo Inhalation CDMO Product Portfolio
- 12.10.5 Iconovo Recent Developments
- 12.11 Kindeva
- 12.11.1 Kindeva Company Information
- 12.11.2 Kindeva Business Overview
- 12.11.3 Kindeva Revenue in Inhalation CDMO Business (2021-2026)
- 12.11.4 Kindeva Inhalation CDMO Product Portfolio
- 12.11.5 Kindeva Recent Developments
- 12.12 Lonza
- 12.12.1 Lonza Company Information
- 12.12.2 Lonza Business Overview
- 12.12.3 Lonza Revenue in Inhalation CDMO Business (2021-2026)
- 12.12.4 Lonza Inhalation CDMO Product Portfolio
- 12.12.5 Lonza Recent Developments
- 12.13 Particle Sciences
- 12.13.1 Particle Sciences Company Information
- 12.13.2 Particle Sciences Business Overview
- 12.13.3 Particle Sciences Revenue in Inhalation CDMO Business (2021-2026)
- 12.13.4 Particle Sciences Inhalation CDMO Product Portfolio
- 12.13.5 Particle Sciences Recent Developments
- 12.14 Proveris
- 12.14.1 Proveris Company Information
- 12.14.2 Proveris Business Overview
- 12.14.3 Proveris Revenue in Inhalation CDMO Business (2021-2026)
- 12.14.4 Proveris Inhalation CDMO Product Portfolio
- 12.14.5 Proveris Recent Developments
- 12.15 Recipharm
- 12.15.1 Recipharm Company Information
- 12.15.2 Recipharm Business Overview
- 12.15.3 Recipharm Revenue in Inhalation CDMO Business (2021-2026)
- 12.15.4 Recipharm Inhalation CDMO Product Portfolio
- 12.15.5 Recipharm Recent Developments
- 12.16 Renejix
- 12.16.1 Renejix Company Information
- 12.16.2 Renejix Business Overview
- 12.16.3 Renejix Revenue in Inhalation CDMO Business (2021-2026)
- 12.16.4 Renejix Inhalation CDMO Product Portfolio
- 12.16.5 Renejix Recent Developments
- 12.17 Ritedose
- 12.17.1 Ritedose Company Information
- 12.17.2 Ritedose Business Overview
- 12.17.3 Ritedose Revenue in Inhalation CDMO Business (2021-2026)
- 12.17.4 Ritedose Inhalation CDMO Product Portfolio
- 12.17.5 Ritedose Recent Developments
- 12.18 Vectura
- 12.18.1 Vectura Company Information
- 12.18.2 Vectura Business Overview
- 12.18.3 Vectura Revenue in Inhalation CDMO Business (2021-2026)
- 12.18.4 Vectura Inhalation CDMO Product Portfolio
- 12.18.5 Vectura Recent Developments
- 12.19 Sanner
- 12.19.1 Sanner Company Information
- 12.19.2 Sanner Business Overview
- 12.19.3 Sanner Revenue in Inhalation CDMO Business (2021-2026)
- 12.19.4 Sanner Inhalation CDMO Product Portfolio
- 12.19.5 Sanner Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst